PHOSPHARE Clinical Trials
Hypophosphatemia has emerged as a side effect of some newer intravenous (IV) iron products. While some incidents can be resolved transiently, complications can occur based on the severity of hypophosphatemia and the time to recover. The PHOSPHARE-IDA trials are two identically-designed, clinical studies that evaluated the risks of hypophosphatemia with two different IV irons. Additional analyses from these data and similar studies were performed.
This section includes links to Pharmacosmos sponsored- publications and selected Pharmacosmos posters. Information contained in these publications may include information that is inconsistent with the FDA approved use of product(s). Pharmacosmos does not recommend the use of its products in a manner that is inconsistent with FDA-approved labeling. Additionally, the content contained in this section is subject to congress copyright permissions.
February 2020 I JAMA
Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia.
Wolf M, Rubin J, Achebe M, et al.
April 2019 I Poster Presented at the 20th Annual NATA Symposium
Pooled analysis of the PHOSPHARE-IDA 04/05 studies: findings relevant to respiratory muscle function
Zoller H, Schaffalitzky de Muckadell P, Wolf M, et al.
March 2022 I J Clin Endocrinol Metab
Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose
Schaefer B, Zoller H, Wolf M, et al.
April 2023 I Gut
Hypophosphatemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial
Zoller H, Wolf M, Blumenstein I, et al.